Company news
In8bio, Inc. (NASDAQ:INAB) news
In8bio, Inc. news releases on 6ix. Latest, May 12, 2022: IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
Press releases — page 3
IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022
IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting
May 4, 2022
IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments
April 12, 2022
IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
March 27, 2022
IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
March 16, 2022
IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme
January 5, 2022
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
December 15, 2021
IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer
December 8, 2021
IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer
November 15, 2021
IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 9, 2021
IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO
November 3, 2021
IN8bio’s Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme
October 26, 2021
IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
September 9, 2021
IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
August 10, 2021
IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors
August 3, 2021
IN8bio Announces Pricing of Initial Public Offering
July 29, 2021